Feb, 2018

Global
News / General News
- Sponsors Tomorrow’s Hero in February and March 2018. : Tomorrow’s Hero showcases young innovators who are transforming the world for a brighter future - Tokyo, February 16, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) launched “CNN Tomorrow’s Hero” as a part of its global corporate brand campaign which in collaboration with CNN. The new multiplatfrom campaign...
Read More
Global
News / General News
- Acquisition enables Astellas to fully utilize proprietary technology to produce pluripotent stem cells that have the potential to lower immunological rejection in numerous therapeutic areas - Tokyo, February 13, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Universal Cells, Inc. (CEO: Claudia Mitchell, “Universal Cells”) today announced that Aste...
Read More
Global
News / General News
Tokyo, February 8, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the results of two Phase 3 trials  (RAJ3 and RAJ4 trials) on Peficitinib hydrobromide (generic name; development code: ASP015K, “Peficitinib”), an oral JAK inhibitor developed by Astellas, in rheumatoid arthritis patients with an inadequate response to existing therapy, demonstra...
Read More
Global
News / General News
Pfizer Contacts: For MediaSally [email protected]  For InvestorsRyan Crowe212-733-8160 [email protected] Astellas Contacts: For MediaTarsis Lopez [email protected] For InvestorsShin Okubo [email protected]  TOKYO and NEW YORK, February 5, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “...
Read More
Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.

Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.

Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.